There is growing international activity and support for the routine implementation of electronically collected patient-reported outcome measures (ePROMs) in everyday practice to inform patient care. In oncology, evidence shows that ePROMs offer a solution for optimising patient surveillance during and after cancer-related treatments. ePROMs can be used in routine care settings to monitor and manage patient symptoms, quality of life (QoL) and experience, enhancing clinical decisions and patient triage. They provide valuable insight into real-world effectiveness and implications of cancer treatments. When integrated into electronic health records ePROMs can be aggregated with other routinely captured data. This provides a real-world big-data ecosystem with ePROMs at the centre of artificial intelligence (AI) models, that can be used for predicting clinical outcomes and building prognostic models; ultimately building clinical-decision support algorithms.
In the UK, the Christie NHS Foundation Trust (Christie) pioneered the routine implementation of ePROMs with patient responses being directly linked to the hospital's electronic health records for real-time monitoring of symptoms and QoL. Launched late 2019, over 80,000 ePROMs have been submitted by more than 25,000 patients, from over 40 cancer groups and treatment pathways.
This talk will provide an overview of the current landscape for the routine implementation of ePROMs in oncology. The Christie experience will be used to demonstrate the facilitators and barriers to the successful implementation of ePROMs at large-scale. Development of the ePROMs service and key impacts on patient outcomes, service efficiencies and experiences of patients and clinicians will be discussed.
